McCullough T Casey, May Noah R, Metro Michael J, Ginsberg Phillip C, Jaffe Jamison S, Harkaway Richard C
Division of Urology, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA.
Urology. 2008 Aug;72(2):370-3. doi: 10.1016/j.urology.2007.12.068. Epub 2008 Mar 12.
To evaluate serum hemoglobin, baseline serum creatinine, serum creatinine at the diagnosis of obstructive hydronephrosis, and the increase in serum creatinine greater than baseline to predict for success in retrograde ureteral stent placement in patients with pelvic malignancies.
In a retrospective chart review, we identified 57 patients at our institution with obstructive hydronephrosis secondary to pelvic malignancies in which retrograde ureteral stent placement was attempted from January 2002 to May 2005. The patient charts were reviewed for the baseline serum creatinine, preoperative serum creatinine and hemoglobin, and serum creatinine at presentation of obstructive hydronephrosis. This population was divided into group 1 (n = 31, 54%), in which retrograde stent placement was successful, and group 2 (n = 26, 46%), in which stent placement failed and subsequent percutaneous nephrostomy tube placement was required. The Student t test was used to determine whether a significant difference existed between the two groups for each laboratory parameter.
The serum hemoglobin and baseline creatinine were not significantly different between the two groups and could not be used to predict for the success or failure of stent placement (P = 0.10 and P = 0.59, respectively). However, the average serum creatinine at presentation of obstructive hydronephrosis was significantly different between group 1 (2.4 +/- 1.4 ng/dL) and group 2 (5.3 +/- 6.3; P = 0.014), as was an increase in serum creatinine greater than baseline (P = 0.002).
The results of this study have shown that the serum creatinine level at the presentation of obstructive hydronephrosis can be used to predict for success in retrograde ureteral stent placement in patients with pelvic malignancies.
评估血清血红蛋白、基线血清肌酐、梗阻性肾盂积水诊断时的血清肌酐以及血清肌酐较基线水平的升高情况,以预测盆腔恶性肿瘤患者逆行输尿管支架置入术的成功率。
在一项回顾性病历审查中,我们确定了2002年1月至2005年5月期间在本机构尝试进行逆行输尿管支架置入术的57例因盆腔恶性肿瘤导致梗阻性肾盂积水的患者。查阅患者病历以获取基线血清肌酐、术前血清肌酐和血红蛋白以及梗阻性肾盂积水出现时的血清肌酐。该人群分为第1组(n = 31,54%),逆行支架置入成功;第2组(n = 26,46%),支架置入失败且随后需要置入经皮肾造瘘管。采用Student t检验确定两组在每个实验室参数上是否存在显著差异。
两组之间的血清血红蛋白和基线肌酐无显著差异,不能用于预测支架置入的成功或失败(P分别为0.10和0.59)。然而,梗阻性肾盂积水出现时第1组(2.4±1.4 ng/dL)和第2组(5.3±6.3;P = 0.014)的平均血清肌酐存在显著差异,血清肌酐较基线水平的升高情况也存在显著差异(P = 0.002)。
本研究结果表明,梗阻性肾盂积水出现时的血清肌酐水平可用于预测盆腔恶性肿瘤患者逆行输尿管支架置入术的成功率。